X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (137) 137
humans (126) 126
imatinib (92) 92
bcr-abl (91) 91
chronic myelogenous leukemia (90) 90
oncology (87) 87
mutation (85) 85
chronic myeloid-leukemia (81) 81
chronic myeloid leukemia (79) 79
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (76) 76
t315i (76) 76
t315i mutation (69) 69
fusion proteins, bcr-abl - genetics (64) 64
resistance (55) 55
t315i mutant (55) 55
hematology (54) 54
leukemia, myelogenous, chronic, bcr-abl positive - genetics (53) 53
imatinib mesylate (51) 51
animals (48) 48
cml (48) 48
leukemia (48) 48
protein kinase inhibitors - therapeutic use (46) 46
fusion proteins, bcr-abl - antagonists & inhibitors (44) 44
protein kinase inhibitors - pharmacology (43) 43
tyrosine kinase (43) 43
hemic and lymphatic diseases (40) 40
fusion proteins, bcr-abl - metabolism (39) 39
tyrosine kinase inhibitor (39) 39
male (34) 34
cell line, tumor (33) 33
dasatinib (33) 33
cancer (32) 32
antineoplastic agents - pharmacology (31) 31
antineoplastic agents - therapeutic use (29) 29
mice (29) 29
ponatinib (29) 29
apoptosis - drug effects (28) 28
chemistry, medicinal (28) 28
drug resistance, neoplasm (28) 28
imatinib resistance (28) 28
benzamides (27) 27
philadelphia-chromosome (27) 27
tyrosine (27) 27
genetic aspects (26) 26
pyrimidines - therapeutic use (26) 26
cell proliferation - drug effects (25) 25
drug resistance, neoplasm - genetics (25) 25
kinases (25) 25
drug resistance (24) 24
drug resistance, neoplasm - drug effects (24) 24
female (24) 24
pharmacology & pharmacy (24) 24
piperazines - therapeutic use (24) 24
biochemistry & molecular biology (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - pathology (23) 23
protein-tyrosine kinases - antagonists & inhibitors (23) 23
pyrimidines - pharmacology (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (22) 22
tyrosine kinase inhibitors (22) 22
adult (21) 21
middle aged (21) 21
research (21) 21
hematology, oncology and palliative medicine (20) 20
models, molecular (20) 20
nilotinib (20) 20
treatment outcome (20) 20
apoptosis (19) 19
philadelphia chromosome (19) 19
piperazines - pharmacology (19) 19
protein kinase inhibitors - chemistry (19) 19
domain mutations (18) 18
in-vitro (18) 18
therapy (18) 18
inhibitors (17) 17
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (17) 17
mechanisms (17) 17
analysis (16) 16
bcr protein (16) 16
c-abl (16) 16
care and treatment (16) 16
cell biology (16) 16
kinase domain mutations (16) 16
proteins (15) 15
aged (14) 14
bcr/abl (14) 14
cells (14) 14
chronic-phase (14) 14
drug design (14) 14
follow-up (14) 14
stem-cells (14) 14
structure-activity relationship (14) 14
abl protein (13) 13
article (13) 13
clinical resistance (13) 13
clinical trials as topic (13) 13
discovery (13) 13
fusion proteins, bcr-abl - chemistry (13) 13
health aspects (13) 13
protein-tyrosine kinase (13) 13
bcr-abl inhibitor (12) 12
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (222) 222
Polish (3) 3
Russian (2) 2
Chinese (1) 1
Croatian (1) 1
French (1) 1
German (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 15, pp. 2875 - 2880
In patients who have chronic‐phase chronic myeloid leukemia (CML) with the Philadelphia chromosome threonine to isoleucine mutation at codon 315, single‐agent... 
threonine to isoleucine mutation at codon 315 (T315I) | Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) | ponatinib | allogeneic stem cell transplantation (allo‐SCT) | chronic myeloid leukemia (CML) | Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) | allogeneic stem cell transplantation (allo-SCT) | RESISTANT | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | MARGINAL STRUCTURAL MODELS | PHASE-2 | INHIBITORS | Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) | CHRONIC MYELOID-LEUKEMIA | Multivariate Analysis | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Transplantation, Homologous | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adult | Female | Retrospective Studies | Imidazoles - therapeutic use | Philadelphia Chromosome | Pyridazines - therapeutic use | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Blast Crisis - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Stem Cell Transplantation - methods | Aged | Blast Crisis - genetics | Mutation | Chemotherapy | Usage | Care and treatment | Gene mutations | Stem cells | Transplantation | Chronic myeloid leukemia | Diagnosis | Research | Cancer | Intervention | Transplants & implants | Leukemia | Bone marrow transplantation | Stem cell transplantation | Blast | Confidence intervals | Bone marrow | Chromosomes | Age | Isoleucine | Cell survival | Acute lymphatic leukemia | Threonine | Myeloid leukemia | Hazards | Crises | Lymphatic leukemia | Patients | Survival | Philadelphia chromosome | Original
Journal Article
Cancer Letters, ISSN 0304-3835, 2011, Volume 312, Issue 1, pp. 91 - 100
Journal Article
Cancer Cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 428 - 442
Journal Article
Biologics: Targets and Therapy, ISSN 1177-5475, 10/2014, Volume 8, pp. 243 - 254
Discusses the use of ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc, in... 
ARIAD | ALL | T315I | EPIC trial | BCR-ABL | PACE trial | Compound mutations | Inhibitors | Treatment | Chronic myeloid leukemia | Protein-tyrosine kinase | Leukemia | Lymphoblastic leukemia | Clinical trials | Kinases | Patients | Cancer therapies | Proteins | Epidermal growth factor | Medical prognosis | Stem cells | Internet | Mutation | Chromosomes | Pharmaceuticals
Journal Article
BBA - General Subjects, ISSN 0304-4165, 04/2019, Volume 1863, Issue 4, pp. 732 - 741
Abl1 is a protein tyrosine kinase whose aberrant activation due to mutations is the culprit of several cancers, most notably chronic myeloid leukaemia. Several... 
Molecular dynamics | Compound mutation | Kinase inhibition | Drug resistance | Ponatinib | Protein kinetics | CHRONIC PHASE | P-LOOP | MOLECULAR-DYNAMICS | C-ABL | BIOCHEMISTRY & MOLECULAR BIOLOGY | BCR-ABL | PARTICLE MESH EWALD | TYROSINE KINASES | BIOPHYSICS | INHIBITOR | IMATINIB RESISTANCE | T315I MUTANT | Proteins | Tyrosine | Biological products | Analysis | Drug therapy
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 383, Issue 2, pp. 220 - 229
Abstract Chronic Myeloid Leukemia (CML) is largely caused by the Philadelphia (Ph) chromosome carrying the Break point Cluster Region-Abelson (BCR-ABL)... 
Hematology, Oncology and Palliative Medicine | Resistance | T315I | Chronic myeloid leukemia | PBA2 | BCR-ABL | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | APOPTOSIS | STATISTICS | TYROSINE KINASE | BLAST CRISIS | KINASE INHIBITOR | CANCER-THERAPY | PHASE | ONCOLOGY | PHILADELPHIA-CHROMOSOME | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Gene Expression Regulation, Neoplastic | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Molecular Targeted Therapy | RNA, Messenger - metabolism | Dose-Response Relationship, Drug | Transfection | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Cell Line | Cell Survival - drug effects | Azulenes - pharmacology | Imatinib Mesylate - pharmacology | RNA, Messenger - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Oxidative Stress - drug effects | G1 Phase Cell Cycle Checkpoints - drug effects | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Evaluation | RNA | Pharmacy | Drugstores | Genetic aspects | Antineoplastic agents | BCR protein | Therapy | Phosphorylation | Imatinib | Myeloid leukemia | Leukemia | Abl protein | Kinases | Drug resistance | Gene expression | Anticancer properties | Gene amplification | Cell growth | Inhibitors | Cell cycle | Inhibition | Fusion protein | Chromosomes | Cancer | G1 phase | Apoptosis
Journal Article
Journal Article
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 05/2011, Volume 71, Issue 9, pp. 3189 - 3195
Acquired point mutations within the BCR-ABL kinase domain represent a common mechanism of resistance to ABL inhibitor therapy in patients with chronic myeloid... 
WILD-TYPE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | TYROSINE KINASE | BCR-ABL | IMATINIB | DRUG-RESISTANCE | DASATINIB | NILOTINIB | T315I MUTANT
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 12/2018, Volume 19, Issue 12, pp. 3317 - 3320
Objective: Chronic Myeloid Leukemia (CML) is caused by a reciprocal translocation between chromosomes 9 and 22, t(9;22) (q34;q11) which encodes for the BCR-ABL... 
BCR/ABL gene | T315I mutation | Chronic Myeloid Leukemia | Tyrosine kinase inhibitor | Short Communications | BCR | ABL gene | tyrosine kinase inhibitor
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2009, Volume 15, Issue 5, pp. 1686 - 1697
Purpose: Resistance to STI571 is an emerging problem for patients with chronic myelogenous leukemia (CML). Mutation in the kinase domain of Bcr-Abl is the... 
Bcr-Abl | triptolide | apoptosis | T315I mutation | CML | STI571 | TRIPTERYGIUM-WILFORDII HOOK | IN-VITRO | ACTIVATION | THERAPY | CANCER CELLS | ONCOLOGY | TYROSINE KINASE INHIBITOR | DEATH | MECHANISMS | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription, Genetic - drug effects | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Male | RNA, Messenger - metabolism | Immunoenzyme Techniques | Young Adult | Proto-Oncogene Proteins c-akt - metabolism | Epoxy Compounds - therapeutic use | Tumor Stem Cell Assay | Phenanthrenes - therapeutic use | Piperazines - therapeutic use | Mutation - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Antineoplastic Agents, Alkylating - therapeutic use | Signal Transduction - drug effects | Mice, Nude | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Mice | Mice, Inbred BALB C | Cell Cycle - drug effects | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Membrane Potential, Mitochondrial - drug effects | Proto-Oncogene Proteins c-akt - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Flow Cytometry | Tripterygium - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adult | Female | Tumor Cells, Cultured | Diterpenes - therapeutic use | RNA, Messenger - genetics | Imatinib Mesylate | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Myeloid Cell Leukemia Sequence 1 Protein | Aged | Cell Proliferation - drug effects | Benzamides | Proto-Oncogene Proteins c-bcl-2 - genetics | Index Medicus
Journal Article